Cited by 256Cholinesterase and Neurodegenerative DiseasesAlzheimer's disease research and treatmentsEnzyme function and inhibition

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

Targeting Beta-Amyloid Pathogenesis Through Acetylcholinesterase Inhibitors

Castro, Ana, Martinez, Ana·2006·Current Pharmaceutical Design

DOI 10.2174/138161206778792985

Open this paper in CoChat — free account

Abstract

Although the hallmarks of neurodegeneration in Alzheimer's brains are well known, one of the current difficulties is related to the lack of solid evidence about the ultimate factors that give rise to the pathogenesis of this disease, creating a great challenge for the definition of efficient treatments for Alzheimer's disease (AD). Current therapeutic option for AD patients is the use of acetylcholinesterase (AChE) inhibitors, which gives only a symptomatic relief. However, recent studies show a long-lasting effect in a certain percentage of patients. In fact, there is accumulating evidence that an AChE has secondary non-cholinergic functions including the processing and deposition of beta-amyloid (Abeta). AChE could play a role in the Abeta metabolism and during an early step in the development of the senile plaque, as revealed by the finding that AChE accelerates Abeta deposition. Considering the non-classical AChE functions, their relationships with AD hallmarks, and the putative role of peripheral anionic site in all these functions, the dual binding site AChE inhibitors may acquire importance for AD treatment. On the other hand, the interference of AChE inhibitors with Abeta processing is not a general rule for this class of compounds with the involvement of other features such as chemical structure and/or genetic regulation. This review highlights the collection of several compounds with an outstanding profile against AChE-induced amyloid aggregation and potent AChE inhibitory activity, indicating the possibility of targeting Abeta through the inhibition of AChE and reveals the emergence of a new generation of AChE inhibitors aiming to be excellent candidate drugs for the future cure of Alzheimer's disease.

Integrity signals

Registry

Crossref · 10.2174/138161206778792985

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A new and rapid colorimetric determination of acetylcholinesterase activity
Ellman, G. L., Courtney, K. D., Andres, V., & Featherstone, R. M. (1961) · Biochemical Pharmacology · doi:10.1016/0006-2952(61)90145-9 · Cited by 27,221
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
The Cation−π Interaction
Jennifer, C., & Dougherty, D. A. (1997) · Chemical Reviews · doi:10.1021/cr9603744 · Cited by 3,518
Acetylcholinesterase — new roles for an old actor
Soreq, H., & Seidman, S. (2001) · Nature reviews. Neuroscience · doi:10.1038/35067589 · Cited by 1,437
Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease
Walsh, D. M., & Selkoe, D. J. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.010 · Cited by 1,207
Acetylcholinesterase Accelerates Assembly of Amyloid-β-Peptides into Alzheimer's Fibrils: Possible Role of the Peripheral Site of the Enzyme
Inestrosa, N. C., Alvarez, A. R., Pérez, C. A., Moreno, R. D., Vicente, M., Linker, C., Casanueva, O. I., Soto, C. A., & Garrido, J. (1996) · Neuron · doi:10.1016/s0896-6273(00)80108-7 · Cited by 1,117
Release of Alzheimer Amyloid Precursor Derivatives Stimulated by Activation of Muscarinic Acetylcholine Receptors
Nitsch, R. M., Slack, B. E., Wurtman, R. J., & Growdon, J. H. (1992) · Science · doi:10.1126/science.1411529 · Cited by 898
beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies.
Bartolini, M., Bertucci, C., Cavrini, V., & Andrisano, V. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01514-9 · Cited by 523
Strategies for disease modification in Alzheimer's disease
Citron, M. (2004) · Nature reviews. Neuroscience · doi:10.1038/nrn1495 · Cited by 430
Cholinesterases: New Roles in Brain Function and in Alzheimer's Disease
Giacobini, E. (2003) · Neurochemical Research · doi:10.1023/a:1022869222652 · Cited by 374
Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils.
Álvarez, A., Opazo, C., Alarcón, R., Garrido, J., & Inestrosa, N. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1245 · Cited by 308
Acetylcholinesterase inhibitors: novel activities of old molecules
Racchi, M. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2003.12.027 · Cited by 291
Modulating astrogliosis after neurotrauma
McGraw, J., Hiebert, G. W., & Steeves, J. D. (2001) · Journal of Neuroscience Research · doi:10.1002/1097-4547(20010115)63:2 · Cited by 277
3-(4-{[Benzyl(methyl)amino]methyl}phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) Inhibits Both Acetylcholinesterase and Acetylcholinesterase-Induced β-Amyloid Aggregation: A Dual Function Lead for Alzheimer's Disease Therapy
Piazzi, L., Rampa, A., Bisi, A., Gobbi, S., Belluti, F., Cavalli, A., Bartolini, M., Andrisano, V., Valenti, P., & Recanatini, M. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0340602 · Cited by 268
Rational Approach To Discover Multipotent Anti-Alzheimer Drugs
Rosini, M., Andrisano, V., Bartolini, M., Bolognesi, M. L., Hrelia, P., Minarini, A., Tarozzi, A., & Melchiorre, C. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049112h · Cited by 228
Design, Synthesis, and Biological Evaluation of Dual Binding Site Acetylcholinesterase Inhibitors: New Disease-Modifying Agents for Alzheimer's Disease
Muñoz-Ruiz, P., Rubio, L., García‐Palomero, E., Dorronsoro, I., del Monte-Millán, M., Valenzuela, R., Usán, P., de Austria, C., Bartolini, M., Andrisano, V., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0503289 · Cited by 221
Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex
Rees, T. M. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00230-0 · Cited by 212
The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease
Rees, T. M., & Brimijoin, S. (2003) · Drugs of today · doi:10.1358/dot.2003.39.1.740206 · Cited by 171 · cited 1×
“Thus, inhibition of AChE might influence the APP processing and Aβ deposition, leading to the reduction of one of the pathological expressions of the disease [23].”
Background
Peripheral and Dual Binding Site Acetylcholinesterase Inhibitors: Implications in treatment of Alzheimers Disease
Castro, A., & Martı́nez, A. (2001) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557013406864 · Cited by 160
Self-citation
Donepezil–tacrine hybrid related derivatives as new dual binding site inhibitors of AChE
Alonso, D. A., Dorronsoro, I., Rubio, L., Muñoz, P., García‐Palomero, E., del Monte, M., Bidon‐Chanal, A., Orozco, M., Luque, F. J., Castro, A., et al. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.09.029 · Cited by 158
Self-citation
Cholinesterase inhibitors increase secretion of APPs in rat brain cortex
Mori, F., Lai, C.-C., Fusi, F., & Giacobini, E. (1995) · Neuroreport · doi:10.1097/00001756-199503000-00012 · Cited by 157
Active-site gorge and buried water molecules in crystal structures of acetylcholinesterase from Torpedo californica 1 1Edited by R. Huber
Koellner, G., Kryger, G., Millard, C. B., Silman, I., Sussman, J. L., & Steiner, T. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3468 · Cited by 146
A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?
Francis, P. T., Nordberg, A. K., & Arnold, S. E. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.12.010 · Cited by 144
Propidium-Based Polyamine Ligands as Potent Inhibitors of Acetylcholinesterase and Acetylcholinesterase-Induced Amyloid-β Aggregation
Bolognesi, M. L., Andrisano, V., Bartolini, M., Banzi, R., & Melchiorre, C. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049156q · Cited by 136
Galantamine hydrobromide: An agent for Alzheimer’s disease
Zarotsky, V., Sramek, J. J., & Cutler, N. R. (2003) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/60.5.446 · Cited by 136
An Overview of Phenserine Tartrate, A Novel Acetylcholinesterase Inhibitor for the Treatment of Alzheimers Disease
Greig, N. H., Sambamurti, K., Yu, Q.-S., Brossi, A. R., Bruinsma, G., & Lahiri, D. K. (2005) · Current Alzheimer Research · doi:10.2174/1567205054367829 · Cited by 122
A review of rivastigmine: A reversible cholinesterase inhibitor
Williams, B. R., Nazarians, A., & Gill, M. A. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80160-1 · Cited by 122
Tacrine alters the secretion of the beta‐amyloid precursor protein in cell lines
Lahiri, D. K., Lewis, S., & Farlow, M. R. (1994) · Journal of Neuroscience Research · doi:10.1002/jnr.490370612 · Cited by 112
The involvement of mitogen‐activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline
Yogev‐Falach, M., Amit, T., Bar‐Am, O., Weinstock, M., & Youdim, M. B. H. (2002) · The FASEB Journal · doi:10.1096/fj.02-0198fje · Cited by 104
Promoter activity of the gene encoding the beta-amyloid precursor protein is up-regulated by growth factors, phorbol ester, retinoic acid and interleukin-1
Lahiri, D. K., & Nall, C. (1995) · Molecular Brain Research · doi:10.1016/0169-328x(95)00078-7 · Cited by 104
The Pharmacotherapy of Alzheimer's Disease Based on the Cholinergic Hypothesis: an Update
Weinstock, M. (1995) · Neurodegeneration · doi:10.1006/neur.1995.0042 · Cited by 104
Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo californica
Kryger, G., Silman, I., & Sussman, J. L. (1998) · Journal of Physiology-Paris · doi:10.1016/s0928-4257(98)80008-9 · Cited by 104
Neuroprotective effects of α-lipoic acid and its positively charged amide analogue
Tirosh, O., Sen, C. K., Roy, S., Kobayashi, M. S., & Packer, L. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00014-3 · Cited by 96
The Adhesion Function on Acetylcholinesterase Is Located at the Peripheral Anionic Site
Johnson, G., & Moore, S. W. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0705 · Cited by 87
Cholinesterase Inhibitors: Xanthostigmine Derivatives Blocking the Acetylcholinesterase-Induced β-Amyloid Aggregation
Belluti, F., Rampa, A., Piazzi, L., Bisi, A., Gobbi, S., Bartolini, M., Andrisano, V., Cavalli, A., Recanatini, M., & Valenti, P. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049515h · Cited by 87
Amyloid‐beta increases acetylcholinesterase expression in neuroblastoma cells by reducing enzyme degradation
Hu, W. T., Gray, N. W., & Brimijoin, S. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01855.x · Cited by 86
Acetylcholinesterase Noncovalent Inhibitors Based on a Polyamine Backbone for Potential Use against Alzheimer's Disease
Melchiorre, C., Andrisano, V., Bolognesi, M. L., Budriesi, R., Cavalli, A., Cavrini, V., Rosini, M., Tumiatti, V., & Recanatini, M. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9810452 · Cited by 81
Cholinesterase inhibitors, β-amyloid precursor protein and amyloid β-peptides in Alzheimer's disease
Lahiri, D. K., Farlow, M. R., Hintz, N., Utsuki, T., & Greig, N. H. (2000) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2000.00309.x · Cited by 77
Development of Bivalent Acetylcholinesterase Inhibitors as Potential Therapeutic Drugs for Alzheimers Disease
Du, D., & Carlier, P. R. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043383412 · Cited by 71
Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid beta-peptide into Alzheimer's filaments.
Inestrosa, N., Alvarez, A. R., & Calderón, F. H. (1996) · PubMed · Cited by 71
Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients
Zimmermann, M., Borroni, B., Cattabeni, F., Padovani, A., & Luca, M. D. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.01.002 · Cited by 67
Acetylcholinesterase Inhibitors as a Starting Point Towards Improved Alzheimers Disease Therapeutics
Recanatini, M., & Valenti, P. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043383313 · Cited by 66
Peripheral binding site is involved in the neurotrophic activity of acetylcholinesterase
Muñoz, F. J., Aldunate, R., & Inestrosa, N. C. (1999) · Neuroreport · doi:10.1097/00001756-199911260-00029 · Cited by 63
Molecular interactions of acetylcholinesterase with senile plaques
Inestrosa, N. C., & Alarcón, R. (1998) · Journal of Physiology-Paris · doi:10.1016/s0928-4257(99)80002-3 · Cited by 61
Memory Deficits Correlating with Acetylcholinesterase Splice Shift and Amyloid Burden in Doubly Transgenic Mice
Rees, T. M., Berson, A., Sklan, E. H., Younkin, L. H., Younkin, S. G., Brimijoin, S., & Soreq, H. (2005) · Current Alzheimer Research · doi:10.2174/1567205054367847 · Cited by 60
Novel Anticholinesterases Based on the Molecular Skeletons of Furobenzofuran and Methanobenzodioxepine
Luo, W., Yu, Q., Zhan, M., Parrish, D. A., Deschamps, J. R., Kulkarni, S. S., Holloway, H. W., Alley, G. M., Lahiri, D. K., Brossi, A. R., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049309+ · Cited by 55
Search for dual function inhibitors for Alzheimer’s disease: Synthesis and biological activity of acetylcholinesterase inhibitors of pyridinium-type and their Aβ fibril formation inhibition capacity
Kapková, P., Alptüzün, V., Frey, P., Erciyas, E., & Holzgrabe, U. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.08.034 · Cited by 54
Role of Acetylcholinesterase Inhibitors in the Metabolism of Amyloid Precursor Protein
Pákáski, M., & Kása, P. (2003) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007033482869 · Cited by 53
Reversible and irreversible acetylcholinesterase inhibitors cause changes in neuronal amyloid precursor protein processing and protein kinase C level in vitro
Pákáski, M., Rakonczay, Z., & Kása, P. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(00)00091-7 · Cited by 53
Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer’s disease
Lanctôt, K. L., Herrmann, N., & Loulou, M. (2003) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0302 · Cited by 51
New Trends in the Design of Drugs Against Alzheimer's Disease
Francotte, P., Graindorge, E., Boverie, S., Tullio, P. D., & Pirotte, B. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043364946 · Cited by 48
Cholinergic Activity and Amyloid Precursor Protein Processing in Aging and Alzheimers Disease
Zhang, X. (2004) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007043482499 · Cited by 43
The Effect of Cholinesterase Inhibitors on the Secretion of APPS from Rat Brain Cortexa
GIACOBINI, E., MORI, F., & Lai, C. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb34451.x · Cited by 42
Effects of Cholinesterase Inhibitors on the Secretion of Beta‐Amyloid Precursor Protein in Cell Culturesa
Lahiri, D. K., Farlow, M. R., Nürnberger, J. I., & Greig, N. H. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb48495.x · Cited by 41
Protein Conformational Misfolding and Amyloid Formation: Characteristics of a New Class of Disorders that Include Alzheimers and Prion Diseases
Thompson, A., & Barrow, C. J. (2002) · Current Medicinal Chemistry · doi:10.2174/0929867023369123 · Cited by 41
Structure-based 3D-QSAR—merging the accuracy of structure-based alignments with the computational efficiency of ligand-based methods
Sippl, W., & Höltje, H. ‐. (2000) · Journal of Molecular Structure THEOCHEM · doi:10.1016/s0166-1280(99)00361-9 · Cited by 39
Donepezil (E2020): a new acetylcholinesterase inhibitor. Review of its pharmacology, pharmacokinetics, and utility in the treatment of Alzheimer’s disease
Heydorn, W. E. (1997) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.6.10.1527 · Cited by 32
Pathways of ligand clearance in acetylcholinesterase by multiple copy sampling
Belle, D. V., Maria, L. D., Iurcu‐Mustata, G., & Wodak, S. J. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3698 · Cited by 32
Structure−Activity Relationships of Acetylcholinesterase Noncovalent Inhibitors Based on a Polyamine Backbone. 3. Effect of Replacing the Inner Polymethylene Chain with Cyclic Moieties
Tumiatti, V., Andrisano, V., Banzi, R., Bartolini, M., Minarini, A., Rosini, M., & Melchiorre, C. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0494366 · Cited by 31
Structure−Activity Relationships of Acetylcholinesterase Noncovalent Inhibitors Based on a Polyamine Backbone. 2. Role of the Substituents on the Phenyl Ring and Nitrogen Atoms of Caproctamine
Tumiatti, V., Rosini, M., Bartolini, M., Cavalli, A., Marucci, G., Andrisano, V., Angeli, P., Banzi, R., Minarini, A., Recanatini, M., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm021055+ · Cited by 30
In vitro and in vivo assessment of the antioxidant activity of melatonin and related indole derivatives.
Štětinová, V., Smetanová, L., Grossmann, V., & Anzenbacher, P. (2002) · PubMed · Cited by 29
Amyloid Processing and Signal Transduction Properties of Antiparkinson‐Antialzheimer Neuroprotective Drugs Rasagiline and TV3326
Youdim, M. B. H., Amit, T., Bar‐Am, O., Weinstock, M., & Yogev‐Falach, M. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07548.x · Cited by 27
Acetylcholinesterase is increased in mouse neuronal and astrocyte cultures after treatment with β-amyloid peptides
Sáez‐Valero, J., Fodero, L. R., White, A. R., Barrow, C. J., & Small, D. H. (2003) · Brain Research · doi:10.1016/s0006-8993(02)04159-8 · Cited by 26
Characterization of the effect of ganstigmine (CHF2819) on amyloid precursor protein metabolism in SH-SY5Y neuroblastoma cells
Mazzucchelli, M., Porrello, E., Villetti, G., Pietra, C., Govoni, S. M., & Racchi, M. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-003-0006-x · Cited by 23
Acetylcholinergic neurotransmission and the β-amyloid cascade: implications for Alzheimer’s disease
Verhoeff, N. P. L. G. (2005) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.5.2.277 · Cited by 21
Reversibility of the effect of tacrine on the secretion of the β-amyloid precursor protein in cultured cells
Lahiri, D. K. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90581-9 · Cited by 21
Heterocyclic inhibitors of AChE acylation and peripheral sites
Bolognesi, M. L., Andrisano, V., Bartolini, M., Cavalli, A., Minarini, A., Recanatini, M., Rosini, M., Tumiatti, V., & Melchiorre, C. (2005) · Il Farmaco · doi:10.1016/j.farmac.2005.03.010 · Cited by 21
Trp279 is involved in the binding of quaternary ammonium at the peripheral site of Torpedo marmorata acetylcholinesterase
Schalk, I. J., Ehret‐Sabatier, L., Bouet, F., Goeldner, M. P., & HIRTH, C. G. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.tb19925.x · Cited by 21
Polymethylene tetraamine backbone as template for the development of biologically active polyamines
Melchiorre, C., Antonello, A., Banzi, R., Bolognesi, M. L., Minarini, A., Rosini, M., & Tumiatti, V. (2002) · Medicinal Research Reviews · doi:10.1002/med.10029 · Cited by 21
Regulation of APP Processing by Intra‐ and Intercellular Signalsa
Buxbaum, J. D., & Greengard, P. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb34441.x · Cited by 20
Peripheral and dual binding site inhibitors of acetylcholinesterase as neurodegenerative disease modifying agents
Dorronsoro, I., Castro, A., & Martı́nez, A. (2003) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.13.11.1725 · Cited by 20
Self-citation
Synthesis and Biological Evaluation of Tacrine‐Thiadiazolidinone Hybrids as Dual Acetylcholinesterase Inhibitors
Dorronsoro, I., Alonso, D. A., Castro, A., del Monte, M., García‐Palomero, E., & Martı́nez, A. (2005) · Archiv der Pharmazie · doi:10.1002/ardp.200400919 · Cited by 19
Self-citation
Cholinesterase Inhibitor Affects the Amyloid Precursor Protein Isoforms in Patients with Alzheimer’s Disease
Liu, H. C., Chi, C.-W., Ko, S.-Y., Wang, H. C., Hong, C. J., Lin, K. N., Wang, P. N., & Liu, T. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000084561 · Cited by 17
Role of acetylcholinesterase inhibitors in the regulation of amyloid β precursor protein (AβPP) metabolism
Racchi, M., Mazzucchelli, M., Lenzken, S. C., Porrello, E., Lanni, C., & Govoni, S. M. (2005) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2005.10.099 · Cited by 16
Potentiation and inhibition of nicotinic effects on striated muscle by the tetramine disulfide benextramine
Benfey, B. G., Brasili, L., Melchiorre, C., & Belleau, B. (1980) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y80-149 · Cited by 8

Sorted by citations

Acetylcholinesterase Inhibitors: Pharmacology and Toxicology
Colovic, M. B., Krstic, D. Z., Lazarevic-Pasti, T. D., Bondzic, A. M., & Vasic, V. M. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311030006 · Cited by 2,611
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease
Leon, R. M., García, A. G., & Marco, J. L. (2011) · Medicinal Research Reviews · doi:10.1002/med.20248 · Cited by 447
CHOLINESTERASES, A TARGET OF PHARMACOLOGY AND TOXICOLOGY
Pohanka, M. (2011) · Biomedical Papers · doi:10.5507/bp.2011.036 · Cited by 377
Revisiting the Cholinergic Hypothesis in Alzheimer's Disease: Emerging Evidence from Translational and Clinical Research
Hampel, H. J., Mesulam, M. M., Cuello, A. C., Khachaturian, A. S., Vergallo, A., Farlow, M. R., Snyder, P. J., Giacobini, E., & Khachaturian, Z. S. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.43 · Cited by 374

See all 256

Authors: Castro, A., & Martinez, A.
ORCID: Castro, Ana
Venue: Current Pharmaceutical Design
Publisher: Bentham Science Publishers Ltd.
Published: 2006-11-01
Volume: 12
Issue: 33
Pages: 4377-4387
ISSN: 1381-6128 (ISSN-L)
DOI: 10.2174/138161206778792985
OpenAlex: W1976042714
Cited by: 207
References: 75
Citations by year: 2026: 7 · 2025: 5 · 2024: 12 · 2023: 7 · 2022: 13 · 2021: 13 · 2020: 12 · 2019: 10 · 2018: 7 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 9 · 2013: 8 · 2012: 15
FWCI: 5.22
Type: journal article
Language: en
Open access: closed
Locations: Current Pharmaceutical Design (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
Keywords: Alzheimer's disease, amyloid-beta, acetylcholinesterase inhibitors, amyloid fibril formation, peripheral anionic site, dual binding site inhibitors, amyloid plaques, amyloid deposition
MeSH terms: Alzheimer Disease, Cholinesterase Inhibitors, Humans, Amyloid beta-Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeting Beta-Amyloid Pathogenesis Through Acetylcholinesterase Inhibitors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks